Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancerBEDFORD, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") NASDAQ:LNTH, the leading radiopharmaceutical-focused company committed to enabling cl…